Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 October 2020 | Story Leonie Bolleurs | Photo Supplied
Adriaan van der Walt
Although several international studies have used temperature metrics to statistically classify their seasonal divisions, a study in which Adriaan van der Walt was involved, would be the first known publication in a South African context using temperature as classification metric.

Gone are the days when we as South Africans would experience a three-month spring season, easing into summer, and then cooling off for three months before we hit winter.

Adriaan van der Walt, Lecturer in the Department of Geography at the University of the Free State (UFS), focuses his research on biometeorology (a specialist discipline exploring the role and climate change in physical and human environments) as well as climatology and geographic information systems.

He recently published an article: ‘Statistical classification of South African seasonal divisions on the basis of daily temperature data’ in the South African Journal of Science.

In this study, which Van der Walt undertook with Jennifer Fitchett, a colleague from the University of the Witwatersrand, data on daily maximum and minimum temperatures was collected from 35 meteorological stations of the South African Weather Service, covering the period between 1980 and 2015.

They went to great lengths to ensure that they had a complete set of data before presenting it to demonstrate seasonal brackets.

First for South Africa

Their statistical seasonal brackets indicate that South Africans now experience longer summers (from October to March), autumn in April and May, winter from June to August, and spring in September.

Although considerable work has been done using rainfall to determine seasonality in Southern Africa, Van der Walt believes that these methods did not work well as there are too many inconsistencies in this approach, as identified by Roffe et al. (2019, South African Geographical Journal). To make matters more complicated – as a semi-arid region, and with desert conditions along the west coast – some regions do not have enough rainfall to use as a classifier.

Temperature, on the other hand, worked well in this study. “Temperature, by contrast, is a continuous variable, and in Southern Africa has sufficient seasonal variation to allow for successful classification,” says Van der Walt.

He continues: “Although several international studies used temperature metrics to statistically classify their seasonal divisions, this study would be the first known publication in a South African context using temperature as classification metric.”

Van der Walt says what we understand as seasons largely relates to phenology – the appearance of blossoms in spring, the colouration and fall of leaves in autumn, and the migration of birds as a few examples. “These phenological shifts are more sensitive to temperature than other climatic variables.”

Seasonal brackets

According to Van der Walt, they believe that a clearly defined and communicated method should be used in defining seasons, rather than just assigning months to seasons.

“One of the most important arguments of our work is that one needs to critically consider breaks in seasons, rather than arbitrarily placing months into seasons, and so we welcome any alternate approaches,” he says.

A number of sectors apply the temperature-based division to their benefit. “For example, in the tourism sector it is becoming increasingly important to align advertising with the season most climatically suitable for tourism,” says Van der Walt.

Temperature-based division is also used to develop adaptive strategies to monitor seasonal changes in temperature under climate change. However, Van der Walt points out that each sector will have its own way of defining seasons. “Seasonal boundaries should nevertheless be clearly communicated with the logic behind them,” he says.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept